Doubling Down on BRCA-Mutated Cancer

Research output: Contribution to journalShort surveypeer-review

1 Scopus citations

Abstract

Immunotherapy is changing the landscape of cancer treatment. Nonetheless, not all malignancies respond, possibly due to low mutational load. Recent work in a TP53−/− BRCA1-mutant murine breast cancer model indicates that double blockade with two immune checkpoint inhibitors increases the number of tumor-infiltrating lymphocytes and overall survival after DNA damaging chemotherapy, whereas single blockade does not. These findings suggest an approach to enhance the impact of immune checkpoint blockade in BRCA-mutated tumors.

Original languageEnglish (US)
Pages (from-to)743-744
Number of pages2
JournalTrends in Cancer
Volume3
Issue number11
DOIs
StatePublished - Nov 2017

Keywords

  • BRCA1
  • breast cancer
  • immune checkpoint
  • immunotherapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Doubling Down on BRCA-Mutated Cancer'. Together they form a unique fingerprint.

Cite this